NEPHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
NEPHROS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$3.68+0.03 (+0.82%)
Close on Oct 19, 2026
- Market cap
- $40.89M
- P/E (TTM)
- 23.0
- Dividend yield
- –
NEPHROS INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Water Filtration [Member] | – | – | – | $9.98M | $10.22M | $8.53M | $10.33M | $5.69M | $3.81M | – | – |
| Pathogen Detection [Member] | – | – | – | – | $187.00K | $29.00K | – | – | – | – | – |
| Consolidated [Member] | – | – | – | $9.98M | $10.22M | $8.56M | $10.33M | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Water Filtration [Member] | – | – | – | -$3.69M | -$2.93M | -$2.00M | -$1.03M | -$2.11M | -$2.18M | – |
| Renal Products [Member] | – | – | – | -$641.00K | -$318.00K | -$1.56M | -$1.53M | -$908.00K | -$44.00K | – |
| Pathogen Detection [Member] | – | – | – | – | -$1.08M | -$717.00K | -$591.00K | – | – | – |
| Consolidated [Member] | – | – | – | -$4.34M | -$3.25M | -$4.48M | -$3.16M | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $18.23M | $14.04M | $14.11M | $9.93M | $10.07M | $8.45M | $10.18M | $5.46M | $3.54M | 97.0% | +29.9% |
| Royalty and Other Revenues [Member] | $555.00K | $127.00K | $128.00K | $46.00K | $152.00K | $108.00K | $152.00K | $230.00K | – | 3.0% | +337.0% |
| Service [Member] | $520.00K | $78.00K | – | – | – | – | – | – | – | 2.8% | +566.7% |
| Other Revenue [Member] | $24.00K | $43.00K | $97.00K | $46.00K | $73.00K | $40.00K | $77.00K | $29.00K | $30.00K | 0.1% | -44.2% |
| License, Royalty and Other Revenues [Member] | – | – | – | – | – | – | – | $230.00K | $265.00K | – | – |
| License Royalty and Other Revenue [Member] | – | – | – | – | $200.00K | $108.00K | $152.00K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Nephros's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.